Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             197 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 62 Abstract withdrawn. 2016
 91 S1 p. S23-
1 p.
 artikel
2 21 Abstract withdrawn. 2016
 91 S1 p. S8-
1 p.
 artikel
3 17 A case of EGFR exon 20 mutation treated with erlotinib Spiliopoulou, P.
 2016
 91 S1 p. S6-S7
2 p.
 artikel
4 26 Access to radical treatment for patients with non-small cell lung cancer Eccles, A.
 2016
 91 S1 p. S9-
1 p.
 artikel
5 82 Accrual to clinical trials – an update Plant, R.E.
 2016
 91 S1 p. S29-S30
2 p.
 artikel
6 90 Accrual to clinical trials in mesothelioma Plant, R.E.
 2016
 91 S1 p. S32-S33
2 p.
 artikel
7 1 A comparative analysis of cancer hotspot mutation profiles in circulating tumour cells, circulating tumour DNA and matched primary lung tumour Leung, M.
 2016
 91 S1 p. S1-
1 p.
 artikel
8 188 ADSCaN: a randomised phase II study of Accelerated, Dose escalated, Sequential, Chemo-radiotherapy in Non-Small Cell Lung Cancer Landau, D.
 2016
 91 S1 p. S68-
1 p.
 artikel
9 60 Afatinib in EGFR mutation positive advanced non-small cell lung cancer Davies, R.S.
 2016
 91 S1 p. S22-
1 p.
 artikel
10 63 Afatinib in non-small cell lung cancer Wood, G.E.
 2016
 91 S1 p. S23-
1 p.
 artikel
11 69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7 O'Byrne, K.J.
 2016
 91 S1 p. S25-
1 p.
 artikel
12 195 A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study Lim, E.
 2016
 91 S1 p. S71-
1 p.
 artikel
13 99 A framework to support the lung cancer nurse specialist in the development and evaluation of nurse-led clinics Morgan, S.
 2016
 91 S1 p. S35-S36
2 p.
 artikel
14 67 Aggressive and unusual metastatic relapses in resected epidermal growth factor receptor (EGFR) mutant adenocarcinoma of lung: biology or chance occurrence? Aslam, S.
 2016
 91 S1 p. S24-
1 p.
 artikel
15 54 ALK translocated NSCLC in the West of Scotland: the first 18 months Mukherjee, L.
 2016
 91 S1 p. S19-
1 p.
 artikel
16 172 A national survey of thoracic surgery units: pre-operative smoking cessation practice shows need for better provision of service Oswald, N.
 2016
 91 S1 p. S62-
1 p.
 artikel
17 129 An audit of a single center use of SABR in primary lung cancer patients Lohnson, K.A.
 2016
 91 S1 p. S46-S47
2 p.
 artikel
18 51 An audit of CTPA imaging within University Hospitals of Leicester Owen, D.J.
 2016
 91 S1 p. S18-
1 p.
 artikel
19 174 An audit of relapse rate in early stage non-small cell lung cancer treated with surgical resection Woolcock, S.
 2016
 91 S1 p. S63-
1 p.
 artikel
20 68 An audit of the use of first-line EGFR TKI treatment in NSCLC patients with EGFR activating mutations at the York Teaching Hospitals and Harrogate and District NHS Foundation Trust Bhagawati-Prasad, V.
 2016
 91 S1 p. S24-S25
2 p.
 artikel
21 32 An evaluation of presenting symptoms in patients referred via the two week wait (2WW) pathway to the chest clinic in a UK district general hospital Reddy, R.
 2016
 91 S1 p. S12-
1 p.
 artikel
22 5 A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential MacDonagh, L.
 2016
 91 S1 p. S2-S3
2 p.
 artikel
23 74 A prospective audit on toxicity and clinical outcomes for platinum-based chemotherapy in stage IIIB/IV non-small cell lung cancer (NSCLC): a West of Scotland analysis Ali, C.
 2016
 91 S1 p. S27-
1 p.
 artikel
24 163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma Minchom, A.R.
 2016
 91 S1 p. S59-
1 p.
 artikel
25 15 A rational organotypic model of human bronchial dysplasia Correia, L.
 2016
 91 S1 p. S6-
1 p.
 artikel
26 159 A retrospective audit to assess compliance with current national guidelines on management of small cell lung cancer and analysis of patient outcome Colley, J.
 2016
 91 S1 p. S58-
1 p.
 artikel
27 139 A retrospective review of lung cancer patients receiving whole brain radiotherapy treated at the Kent Oncology Centre (KOC) in 2014, audited against the QUARTZ trial Hegarty, G.
 2016
 91 S1 p. S50-S51
2 p.
 artikel
28 164 A review of an indwelling pleural catheter service Aujayeb, A.
 2016
 91 S1 p. S60-
1 p.
 artikel
29 53 A review of a thoracoscopy service Aujayeb, A.
 2016
 91 S1 p. S19-
1 p.
 artikel
30 149 A review of the accuracy and efficacy of immobilisation used for patients receiving radical radiotherapy for lung cancer Todd, L.
 2016
 91 S1 p. S54-
1 p.
 artikel
31 40 Are we staging N2 disease in non-small cell lung cancer as accurately as possible? The NHS Tayside experience Hart, J.
 2016
 91 S1 p. S14-S15
2 p.
 artikel
32 128 A study comparing lung SABR plans generated using Multiplan for CyberKnife and Monaco for Elekta Versa 6FFF Dalling, K.
 2016
 91 S1 p. S46-
1 p.
 artikel
33 16 A surprise at the end of the scope – non-Hodgkin's B-cell lymphoma presenting as a solitary endobronchial lesion – a rare and unusual presentation Terrington, D.
 2016
 91 S1 p. S6-
1 p.
 artikel
34 144 Audit of palliative whole brain radiotherapy (WBRT) in patients with non-small cell lung cancer (NSCLC) treated at the Oxford Cancer Centre over 2½ years Shakir, R.
 2016
 91 S1 p. S52-S53
2 p.
 artikel
35 81 Audit of 1 year survival for patients receiving chemotherapy for NSCLC – all comers Allison, J.L.E.
 2016
 91 S1 p. S29-
1 p.
 artikel
36 44 Audit on hyponatraemia in lung cancer – prevalence and clinical significance Roux, R.
 2016
 91 S1 p. S16-
1 p.
 artikel
37 166 Audit on the characteristics of lung cancer patients who receive BSC (best supportive care) Harris, M.
 2016
 91 S1 p. S60-
1 p.
 artikel
38 Author Index 2016
 91 S1 p. S73-S77
5 p.
 artikel
39 113 Barriers to surgery in early stage lung cancer – the East Sussex experience Parker, L.
 2016
 91 S1 p. S40-
1 p.
 artikel
40 38 Brain imaging before lung cancer resection? An analysis of data from Bristol Hudson, Z.
 2016
 91 S1 p. S14-
1 p.
 artikel
41 103 BREATHE (Breath, Rehabilitation, Exercise And Transforming Health Education) – a cancer survivor initiative program at University College London Hospital Gauntlett, S.
 2016
 91 S1 p. S37-
1 p.
 artikel
42 123 Breath-hold technique during radical radiotherapy for non-small-cell lung cancer (NSCLC) Hollingdale, A.E.
 2016
 91 S1 p. S44-
1 p.
 artikel
43 96 Building international oncology nurse collaborations to improve thoracic oncology patient care Guerin, M.
 2016
 91 S1 p. S34-
1 p.
 artikel
44 7 Cancer stem cells: targeting aldehyde dehydrogenase 1 (ALDH1) as a novel strategy to overcome cisplatin resistance in NSCLC MacDonagh, L.
 2016
 91 S1 p. S3-
1 p.
 artikel
45 183 Can 30 day-mortality after lung cancer resection be used as an individual surgeon quality outcome? National data from the United Kingdom Proli, C.
 2016
 91 S1 p. S66-
1 p.
 artikel
46 19 Can oral methotrexate improve survival in mesothelioma? Case report Rizvi, S.A.J.
 2016
 91 S1 p. S7-
1 p.
 artikel
47 80 Can we give SACT to patients with NSCLC on time and at full dose? Allison, J.L.E.
 2016
 91 S1 p. S29-
1 p.
 artikel
48 176 Carcinoid lung cancer: 4-year data of patients treated in a tertiary centre Asa'Ari, K. Abi Musa
 2016
 91 S1 p. S63-S64
2 p.
 artikel
49 180 Cardiothoracic surgeons can provide a safe and effective thoracic surgery service Rajnish, R.K.
 2016
 91 S1 p. S65-
1 p.
 artikel
50 35 Changing patterns of hospital admissions for lung cancer patients in Ireland, 2005 to 2014 Quintyne, K.I.
 2016
 91 S1 p. S13-
1 p.
 artikel
51 23 Characteristics of lung cancer patients diagnosed following emergency admission Ruparel, M.
 2016
 91 S1 p. S8-S9
2 p.
 artikel
52 154 Chemotherapy treatment rates and survival in poor performance status small cell lung cancer at a district general hospital Reinius, M.
 2016
 91 S1 p. S56-
1 p.
 artikel
53 6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC MacDonagh, L.
 2016
 91 S1 p. S3-
1 p.
 artikel
54 157 Comparison of outcomes for early small cell lung cancer (SCLC) treated with surgery versus concurrent chemo radiation (CTRT) Foy, V.
 2016
 91 S1 p. S57-S58
2 p.
 artikel
55 181 Comparison of outcomes of sleeve lobectomy for lung carcinoid versus non-small cell lung cancer Lang, P.
 2016
 91 S1 p. S65-S66
2 p.
 artikel
56 47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden Kordbacheh, T.
 2016
 91 S1 p. S17-
1 p.
 artikel
57 121 Continuous hyperfractionated accelerated radiotherapy (CHART) using volumetric modulated arc therapy (VMAT) for locally advanced non-small cell lung cancer (NSCLC) – the clinical experience Shrimali, R.
 2016
 91 S1 p. S43-S44
2 p.
 artikel
58 13 Creation of a large single-centre retrospective tumour archive Das, M.
 2016
 91 S1 p. S5-
1 p.
 artikel
59 57 Crizotinib in clinical practice: the North East of England's experience Hall, S.
 2016
 91 S1 p. S21-
1 p.
 artikel
60 58 Crizotinib toxicity, dose adjustments and initial response: a single centre experience Arunsingh, M.
 2016
 91 S1 p. S21-S22
2 p.
 artikel
61 101 Crossing the boundaries with proactive care for lung cancer patients – developing and testing a new model of care Wells, L.M.
 2016
 91 S1 p. S36-
1 p.
 artikel
62 126 CyberKnife® for early stage non-small cell lung cancer (NSCLC) at a tertiary referral centre – results of the first two years of treatment at Birmingham Sangha, V.
 2016
 91 S1 p. S46-
1 p.
 artikel
63 84 30 day mortality following systemic anti-cancer treatment (SACT) in lung cancer: experience from a cancer unit Jessop, S.
 2016
 91 S1 p. S30-
1 p.
 artikel
64 78 Denosumab in lung cancer Wright, F.A.
 2016
 91 S1 p. S28-
1 p.
 artikel
65 2 Detecting and monitoring somatic mutations in circulating cell free tumour DNA in patients with lung cancer Nelmes, D.J.
 2016
 91 S1 p. S1-
1 p.
 artikel
66 42 Determinants of intra-procedure hypoxia during EBUS for cancer Smyth, R.
 2016
 91 S1 p. S15-
1 p.
 artikel
67 34 Developing an integrated lung cancer system in Greater Manchester: a 3-step framework Bayman, N.
 2016
 91 S1 p. S12-
1 p.
 artikel
68 109 Development of a new online map to review standards of lung cancer services in the UK Townsend, C.N.
 2016
 91 S1 p. S39-
1 p.
 artikel
69 145 Documentation of DVLA guidance provision for patients with brain metastases Patel, P.
 2016
 91 S1 p. S53-
1 p.
 artikel
70 124 Dosimetric evaluation of adaptive planning during radiotherapy (ART) in radical lung to ensure tumour coverage and/or minimise doses to organs at risk – case discussion Morenc, A.
 2016
 91 S1 p. S45-
1 p.
 artikel
71 142 Dosimetric findings in patients with moderate to severe late toxicity following SABR for lung cancer Aznar-Garcia, L.
 2016
 91 S1 p. S51-S52
2 p.
 artikel
72 48 Do stage I lung cancer patients have lung cancer symptoms? Higgins, E.M.
 2016
 91 S1 p. S17-
1 p.
 artikel
73 171 Early chest mechanics changes post lung cancer resection: the effect of post operative pulmonary complications on chest wall mechanics Elshafie, G.
 2016
 91 S1 p. S62-
1 p.
 artikel
74 173 Early chest mechanics changes post lung cancer resection: the effect of thoracic nerve blocks Elshafie, G.
 2016
 91 S1 p. S62-S63
2 p.
 artikel
75 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results Gettinger, S.N.
 2016
 91 S1 p. S20-S21
2 p.
 artikel
76 9 EGFR and EML4-Alk testing for non-small cell lung cancer patients – a single centre experience Chatterjee, S.
 2016
 91 S1 p. S4-
1 p.
 artikel
77 3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice Pender, A.
 2016
 91 S1 p. S2-
1 p.
 artikel
78 117 Electronic cigarettes: a survey of observed patient use and attitudes among members of the British Thoracic Oncology Group Sherratt, F.C.
 2016
 91 S1 p. S42-
1 p.
 artikel
79 136 Electronic patient reported outcomes significantly improved toxicity data collection and were acceptable to both patients and clinicians in lung cancer radiotherapy outpatient clinics Shears, A.
 2016
 91 S1 p. S49-S50
2 p.
 artikel
80 39 Endobronchial ultrasound – a review of this novel service in Altnagelvin Hospital Moore, I.
 2016
 91 S1 p. S14-
1 p.
 artikel
81 65 Erlotinib: how good is it in a Scottish population? Gallanagh, M.
 2016
 91 S1 p. S23-S24
2 p.
 artikel
82 106 Evaluation of quality of life in patients with primary and metastatic lung cancer following radiofrequency ablation Beeson, J.
 2016
 91 S1 p. S38-
1 p.
 artikel
83 95 Evaluation of the lung cancer nurse specialist communication workshop De Normanville, C.
 2016
 91 S1 p. S34-
1 p.
 artikel
84 89 Experience of the treatment of malignant mesothelioma at a UK centre Plant, R.E.
 2016
 91 S1 p. S32-
1 p.
 artikel
85 8 Exploitation of the vitamin A/retinoic acid axis in the re-sensitisation of cisplatin resistant NSCLC cells MacDonagh, L.
 2016
 91 S1 p. S3-S4
2 p.
 artikel
86 61 Factors affecting sensitising EGFR mutation rate and cell type in stage IIIB/IV lung cancer Kennedy, M.P.T.
 2016
 91 S1 p. S22-S23
2 p.
 artikel
87 92 Final diagnosis for patients referred to pleural clinic Mackenzie, J.
 2016
 91 S1 p. S33-
1 p.
 artikel
88 116 Gene mutation profile of non-smokers compared to smokers participating in the CRUK stratified medicines programme at a single institution De Sousa, P.
 2016
 91 S1 p. S41-
1 p.
 artikel
89 110 Geographical disparities in access to lung cancer services in England Murage, P.
 2016
 91 S1 p. S39-
1 p.
 artikel
90 88 Global estimation of mesothelioma deaths Chimed-Ochir, O.
 2016
 91 S1 p. S32-
1 p.
 artikel
91 141 HALT trial: stereotactic radiotherapy for oligo-progressive disease (OPD) in oncogene-addicted lung tumours – results of a national trial feasibility questionnaire Bainbridge, H.
 2016
 91 S1 p. S51-
1 p.
 artikel
92 108 Healthcare costs associated with lung cancer diagnosed at emergency hospitalisation Kennedy, M.P.T.
 2016
 91 S1 p. S38-S39
2 p.
 artikel
93 70 Heterogeneity of programmed death-ligand 1 expression in multifocal lung cancer Mansfield, A.S.
 2016
 91 S1 p. S25-S26
2 p.
 artikel
94 4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC Barr, M.P.
 2016
 91 S1 p. S2-
1 p.
 artikel
95 49 Increasing incidence of non-smoking lung cancer: presentation of patients with early disease to a tertiary institution in the UK Cufari, M.E.
 2016
 91 S1 p. S17-S18
2 p.
 artikel
96 37 Is it all in the head? The value of performing a CT brain in staging patients with non-small cell lung cancer (NSCLCa) Morrison, K.A.
 2016
 91 S1 p. S13-S14
2 p.
 artikel
97 191 Isotoxic intensity modulated radiotherapy (IMRT) in stage III non small cell lung cancer (NSCLC) – a feasibility study Groom, N.
 2016
 91 S1 p. S69-S70
2 p.
 artikel
98 132 Is stereotactic ablative radiotherapy (SABR) a safe treatment for multiple primary lung cancer (MPLC) non-small cell lung cancer (NSCLC)? Murray, P.F.
 2016
 91 S1 p. S48-
1 p.
 artikel
99 50 Is the development of primary lung adenocarcinoma simply due to “bad luck”? Cufari, M.E.
 2016
 91 S1 p. S18-
1 p.
 artikel
100 134 Long term local tumour control in inoperable NSCLC treated with accelerated hypofractionated radiotherapy and concurrent cisplatinum and vinorelbine Kelly, V.
 2016
 91 S1 p. S49-
1 p.
 artikel
101 29 Lung cancer diagnostic pathway from date of abnormal chest X-ray to treatment Khan, S. Leyakathali
 2016
 91 S1 p. S10-S11
2 p.
 artikel
102 102 Lung cancer in Ireland 2010–2015 – are we making progress? McNamara, A.
 2016
 91 S1 p. S36-S37
2 p.
 artikel
103 148 Lung toxicity and patient outcomes correlated to V5, V20, lung and PTV volume in patients treated radically for non-small cell lung cancer at the Beatson West of Scotland Cancer Centre Harrand, R.
 2016
 91 S1 p. S54-
1 p.
 artikel
104 59 Management of ALK rearranged non-small cell lung cancer (NSCLC) diagnosed at the Leeds Cancer Centre between 2013 and 2015 Sun, F.
 2016
 91 S1 p. S22-
1 p.
 artikel
105 64 Management of EGFR tyrosine kinase inhibitor associated skin toxicity: a single centre experience Thomas, L.
 2016
 91 S1 p. S23-
1 p.
 artikel
106 158 Management of small cell lung cancer in Manchester's Northwest Sector Mehdi, S.B.
 2016
 91 S1 p. S58-
1 p.
 artikel
107 83 Management of stage 4 NSCLC patients with performance status of 2 Patterson, D.M.
 2016
 91 S1 p. S30-
1 p.
 artikel
108 87 Mesothelin-targeted immunotherapy CRS-207 plus chemotherapy as treatment for malignant pleural mesothelioma (MPM) Hassan, R.
 2016
 91 S1 p. S31-S32
2 p.
 artikel
109 12 mRNA helicases as therapeutic targets in lung cancer Raza, F.
 2016
 91 S1 p. S5-
1 p.
 artikel
110 168 Multidisciplinary follow up of patients with advanced lung cancer Saunders, Y.
 2016
 91 S1 p. S61-
1 p.
 artikel
111 135 Multiple training interventions significantly improves PET/CT based lung cancer radiotherapy target volume delineation following an IAEA based delineation protocol Konert, T.
 2016
 91 S1 p. S49-
1 p.
 artikel
112 10 Multiplex genotyping of matched EBUS TBNA and cfDNA samples in advanced NSCLC patients Lyons, J.
 2016
 91 S1 p. S4-
1 p.
 artikel
113 150 Ninety-day mortality following radical radiotherapy for lung cancer Nolan, E.
 2016
 91 S1 p. S54-S55
2 p.
 artikel
114 18 Non-small cell lung cancer (NSCLC) and longitudinally extensive transverse myelitis (LETM): is surgical risk worthwhile? A case report Antonopoulos, A.
 2016
 91 S1 p. S7-
1 p.
 artikel
115 127 Outcome of CyberKnife radiosurgery for early stage lung cancer Mahmood, B.
 2016
 91 S1 p. S46-
1 p.
 artikel
116 156 Outcomes after surgery for small cell lung cancer in the West of Scotland Hanna, C.
 2016
 91 S1 p. S57-
1 p.
 artikel
117 76 Outcomes and tolerability of second line treatment for non small cell lung cancer (NSCLC) Salih, Z.
 2016
 91 S1 p. S27-S28
2 p.
 artikel
118 31 Outcomes following the implementation of British Thoracic Society Nodule Guidelines through a formal multidisciplinary team process – a district general hospital experience Budd, R.
 2016
 91 S1 p. S11-S12
2 p.
 artikel
119 98 Outcomes from a novel nurse led telephone clinic, post-thoracic surgery Love, J.
 2016
 91 S1 p. S35-
1 p.
 artikel
120 161 Outcomes of concurrent chemoradiotherapy in small cell lung cancer Mccann, B.
 2016
 91 S1 p. S59-
1 p.
 artikel
121 140 Outcomes of salvage radiotherapy in the treatment of NSCLC with loco-regional relapse Calisaya, P.
 2016
 91 S1 p. S51-
1 p.
 artikel
122 75 Palliative second-line systemic treatment of non-small cell lung cancer within a UK cancer centre Stokoe, I.M.
 2016
 91 S1 p. S27-
1 p.
 artikel
123 147 Palliative thoracic radiotherapy in locally advanced/metastatic non-small cell lung cancer (NSCLC) Maclennan, K.
 2016
 91 S1 p. S53-S54
2 p.
 artikel
124 30 Patient experience of a telephone nodule follow-up clinic Ross, C.L.
 2016
 91 S1 p. S11-
1 p.
 artikel
125 105 Patient journey interviews: a tool for service improvement in thoracic surgery Dixon, S.
 2016
 91 S1 p. S37-
1 p.
 artikel
126 33 Patient reported experience measures in improving rapid access lung cancer clinic holistic care outcomes Tang, H.K.C.
 2016
 91 S1 p. S12-
1 p.
 artikel
127 41 Patient satisfaction during bronchoscopy and endobronchial ultrasound performed under conscious sedation Tufail, M.
 2016
 91 S1 p. S15-
1 p.
 artikel
128 182 Patient satisfaction with quality of information in lung cancer surgery Oswald, N.
 2016
 91 S1 p. S66-
1 p.
 artikel
129 120 Patient statisfaction with lung cancer survivorship clinic Boland, A.C.
 2016
 91 S1 p. S43-
1 p.
 artikel
130 45 “PAXgene Tissue” – a novel alternative to formalin fixation for diagnostic pathology Southwood, M.
 2016
 91 S1 p. S16-
1 p.
 artikel
131 160 PCI – improving on a parallel pair Smith, D.
 2016
 91 S1 p. S58-S59
2 p.
 artikel
132 107 Performance status, not age, influences decision-to-treat in non small cell lung cancer (NSCLC) Mactier, K.
 2016
 91 S1 p. S38-
1 p.
 artikel
133 14 Phagocytic behaviour in lung adenocarcinoma cells: clinical implications and cellular mechanisms Mackay, H.L.
 2016
 91 S1 p. S5-S6
2 p.
 artikel
134 193 PIT: a phase III trial of Prophylactic Irradiation of Tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention Bayman, N.
 2016
 91 S1 p. S70-S71
2 p.
 artikel
135 125 Planning study comparing the use of photon radiation therapy to proton therapy for superior sulcus tumours (SSTs) Wong, S.
 2016
 91 S1 p. S45-
1 p.
 artikel
136 165 Pleural service in a district general hospital Conroy, K.
 2016
 91 S1 p. S60-
1 p.
 artikel
137 175 Pneumonectomy for lung cancer: long-term outcome of 15-year experience of a single center Hussain, A.
 2016
 91 S1 p. S63-
1 p.
 artikel
138 22 Pneumoperitoneum following CT guided percutaneous lung biopsy Ali, H.
 2016
 91 S1 p. S8-
1 p.
 artikel
139 178 Postchemotherapy resection of malignant mediastinal germ cell tumours – does persistent malignancy matter? Di Martino, M.
 2016
 91 S1 p. S64-
1 p.
 artikel
140 115 Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer Mansfield, A.S.
 2016
 91 S1 p. S41-
1 p.
 artikel
141 179 Predictors of mortality in thoracic surgery for high risk patients with lung cancer Al-Najjar, H.
 2016
 91 S1 p. S64-S65
2 p.
 artikel
142 131 Preliminary results of prospective data for patients receiving stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer (NSCLC) Pickles, R.L.
 2016
 91 S1 p. S47-S48
2 p.
 artikel
143 46 PRImary versus Metastasis using Iontorrent Next Generation Sequencing (PRIMINGS) Moore, D.A.
 2016
 91 S1 p. S16-S17
2 p.
 artikel
144 66 Promoting awareness and improving education to more effectively manage toxicity of EGFR TKI medication; information for patients and primary care physicians Rush, H.
 2016
 91 S1 p. S24-
1 p.
 artikel
145 187 Pulmonary Metastasectomy in Colorectal Cancer: the PulMiCC trial Treasure, T.
 2016
 91 S1 p. S67-S68
2 p.
 artikel
146 43 Quality standards for invasive tests for diagnosis and staging of lung carcinoma: a retrospective review at a tertiary referral hospital Hobbins, S.
 2016
 91 S1 p. S15-S16
2 p.
 artikel
147 79 Re-audit of cisplatin (>70 mg/m2) induced nausea and vomiting, following the introduction of aprepitant Mack, E.
 2016
 91 S1 p. S29-
1 p.
 artikel
148 146 Retrospective audit of treatment outcomes from palliative thoracic radiotherapy – a single centre experience Aladili, Z.
 2016
 91 S1 p. S53-
1 p.
 artikel
149 94 Roy Castle Lung Cancer Foundation: making the case for LCNSs Fox, J.
 2016
 91 S1 p. S34-
1 p.
 artikel
150 133 SABR for lung cancer – a case for development of a service in Tayside Ponnusamy, S.
 2016
 91 S1 p. S48-S49
2 p.
 artikel
151 155 Should we be more aggressive in treating patients with small cell lung cancer? Lim, J.
 2016
 91 S1 p. S56-S57
2 p.
 artikel
152 100 Singing for breathing: a community based intervention for chronic respiratory diseases Eastwood, C.
 2016
 91 S1 p. S36-
1 p.
 artikel
153 153 Small cell lung cancer – an email alert system to reduce time to first treatment Nicholas, O.J.
 2016
 91 S1 p. S56-
1 p.
 artikel
154 118 Smoking habits in lung cancer patients and their carers and audit of smoking advice given Pankhania, D.
 2016
 91 S1 p. S42-
1 p.
 artikel
155 169 Social prescribing – can social groups address patients' and carers' emotional and wellbeing needs when diagnosed with mesothelioma or lung cancer? Lemon, J.
 2016
 91 S1 p. S61-
1 p.
 artikel
156 112 Spreading the word – using consumers effectively Rawlinson, J.
 2016
 91 S1 p. S40-
1 p.
 artikel
157 138 Stage I non small cell lung cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative radiotherapy Thippu Jayaprakash, K.
 2016
 91 S1 p. S50-
1 p.
 artikel
158 71 Statins as novel therapeutic agents in targeting TAMs within human NSCLC microenvironment Aldujaily, E.A.
 2016
 91 S1 p. S26-
1 p.
 artikel
159 130 Stereotactic ablative body radiotherapy (SABR): Weston Park Hospital experience Das, T.S.
 2016
 91 S1 p. S47-
1 p.
 artikel
160 185 Surgical resection of lung cancer patients referred from district general hospital – our experience Mehdi, S.B.
 2016
 91 S1 p. S67-
1 p.
 artikel
161 143 Survey of UK practice of palliative radiotherapy post chemotherapy in stage 4 NSCLC Lee, C.E.
 2016
 91 S1 p. S52-
1 p.
 artikel
162 73 “Switch Maintenance” chemotherapy with pemetrexed after carboplatin and vinorelbine in advanced NSCLC Davies, R.
 2016
 91 S1 p. S26-S27
2 p.
 artikel
163 77 Systemic therapy is safe and effective in octogenarians with advanced lung cancer Rush, H.
 2016
 91 S1 p. S28-
1 p.
 artikel
164 194 SYSTEMS-2: a randomised phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma Ashton, M.
 2016
 91 S1 p. S71-
1 p.
 artikel
165 27 Talc pleurodesis via chest drain vs indwelling pleural catheter (IPC) for managing malignant pleural effusions in a district general hospital Adizie, J.B.
 2016
 91 S1 p. S10-
1 p.
 artikel
166 192 TARGET trial – randomised controlled trial to compare the diagnostic yield of positron emission tomography computed tomography (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy De Fonseka, D.
 2016
 91 S1 p. S70-
1 p.
 artikel
167 190 Testing the feasibility of establishing a cohort of lung cancer patients to investigate recovery following radiotherapy with curative intent Calman, L.
 2016
 91 S1 p. S69-
1 p.
 artikel
168 184 The benefits of pneumonectomy avoidance through broncho-angioplastic techniques for main stem non-small cell lung cancers (NSCLC) Paik, A.
 2016
 91 S1 p. S66-S67
2 p.
 artikel
169 91 The effect of benign and malignant pleural disease on chest wall mechanics Elshafie, G.
 2016
 91 S1 p. S33-
1 p.
 artikel
170 177 The effect of lung cancer resection on chest wall mechanics of COPD patients Elshafie, G.
 2016
 91 S1 p. S64-
1 p.
 artikel
171 152 The feasibility of conducting radiotherapy trials in patients with stage II–III non-small cell lung cancer (NSCLC) not eligible for chemotherapy and/or surgery: results of a clinical audit over an 18-month period Salem, A.
 2016
 91 S1 p. S55-
1 p.
 artikel
172 167 The Hillingdon Hospital NHS Trust Test community case study – adult cancer survivorship programme: tumour group lung Lynch, J.
 2016
 91 S1 p. S60-S61
2 p.
 artikel
173 93 The identification and appreciation of the specific needs of lung cancer patients receiving surgery and adjuvant chemotherapy Peplow, K.
 2016
 91 S1 p. S33-
1 p.
 artikel
174 24 The impact of an inpatient acute oncology service on new lung cancer diagnoses Ayub, S.
 2016
 91 S1 p. S9-
1 p.
 artikel
175 25 The impact of emergency presentations on lung cancer survival in a district general hospital – a review of new in-patient lung cancer referrals to the respiratory specialist nurse service at Conquest Hospital, East Sussex, UK Ferguson, R.
 2016
 91 S1 p. S9-
1 p.
 artikel
176 151 The incidence of thoracic re-irradiation at 3 UK cancer centres following curative intent radiotherapy for non-small cell lung cancer Scobie, S.
 2016
 91 S1 p. S55-
1 p.
 artikel
177 55 The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained Greystoke, A.
 2016
 91 S1 p. S20-
1 p.
 artikel
178 104 The LEAD programme: a novel approach to continuing professional development for lung cancer nurse specialists Borthwick, D.
 2016
 91 S1 p. S37-
1 p.
 artikel
179 170 The role of cryotherapy for obstructive, tracheobronchial lesions: a review Beeson, J.
 2016
 91 S1 p. S61-S62
2 p.
 artikel
180 72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer Dumas, L.
 2016
 91 S1 p. S26-
1 p.
 artikel
181 48 The safety profile of VATS pleural biopsy Vozza, A.
 2016
 91 S1 p. S79-
1 p.
 artikel
182 11 The switch to invasiveness in lung adenocarcinoma Moore, D.A.
 2016
 91 S1 p. S4-S5
2 p.
 artikel
183 36 The use of audit to improve resection rates in non-small cell lung cancer in Essex Van Zeller, C.
 2016
 91 S1 p. S13-
1 p.
 artikel
184 122 To determine ideal gross tumour volumes and PTV expansion using four-dimensional computed tomography for the treatment of lung cancer Goyal, N.
 2016
 91 S1 p. S44-
1 p.
 artikel
185 20 Transformation of EML4/ALK positive adenocarcinoma of the lung to small cell lung cancer following ALK targeted therapy Lees, C.E.
 2016
 91 S1 p. S8-
1 p.
 artikel
186 119 Treatment outcomes in stage I lung cancer Kennedy, M.P.T.
 2016
 91 S1 p. S42-S43
2 p.
 artikel
187 52 Ultrasound guided fine needle aspiration (FNA) of supraclavicular neck nodes in patients with suspected lung cancer – a retrospective review of practice in North Devon district hospital Mitchell, T.
 2016
 91 S1 p. S18-S19
2 p.
 artikel
188 162 Uptake of prophylactic cranial irradiation in patients with small cell lung cancer within the Mount Vernon Cancer Network Tharmalingam, H.
 2016
 91 S1 p. S59-
1 p.
 artikel
189 114 Use of routine healthcare data for the estimation of disease outcomes in locally advanced non-small cell lung cancer (LA NSCLC) Wong, S.
 2016
 91 S1 p. S40-S41
2 p.
 artikel
190 186 Using electronic patient records as an effective tool to screen and improve recruitment to a Phase 1 trial in non-small cell lung cancer Haslett, K.
 2016
 91 S1 p. S67-
1 p.
 artikel
191 97 Using Your Voice 2014 – how to use your nursing voice at the MDT Magee, L.
 2016
 91 S1 p. S35-
1 p.
 artikel
192 189 VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot: the VIOLET study Lim, E.
 2016
 91 S1 p. S68-S69
2 p.
 artikel
193 85 What are the commonest toxicities for patients receiving chemotherapy for NSCLC? – a look at 6 months of data for all comers Allison, J.L.E.
 2016
 91 S1 p. S30-S31
2 p.
 artikel
194 86 When RON MET TAM: potential interventions for mesothelioma therapy Baird, A.
 2016
 91 S1 p. S31-
1 p.
 artikel
195 28 Where and why do patients with advanced lung cancer present in Wolverhampton? Hancock, J.
 2016
 91 S1 p. S10-
1 p.
 artikel
196 111 Why involve consumers in cancer research? Rawlinson, J.
 2016
 91 S1 p. S39-S40
2 p.
 artikel
197 137 10 years of CHART (continuous hyperfractionated accelerated radiotherapy) for non-small cell lung cancer (NSCLC) at NCCC Pickles, R.L.
 2016
 91 S1 p. S50-
1 p.
 artikel
                             197 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland